{
    "id": 504,
    "fullName": "GNAQ Q209L",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "GNAQ Q209L is a hotspot mutation that lies within the GTPase domain of the Gnaq protein (PMID: 19936769). Q209L confers a loss of function on Gnaq protein as indicated by activation of Erk signaling, transformation of cultured cells, and increased tumor growth in mouse models (PMID: 1328859, PMID: 19078957, PMID: 21083380).",
            "references": [
                {
                    "id": 12544,
                    "pubMedId": 1328859,
                    "title": "Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/1328859"
                },
                {
                    "id": 909,
                    "pubMedId": 19936769,
                    "title": "Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19936769"
                },
                {
                    "id": 8702,
                    "pubMedId": 19078957,
                    "title": "Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19078957"
                },
                {
                    "id": 8762,
                    "pubMedId": 21083380,
                    "title": "Mutations in GNA11 in uveal melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21083380"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2776,
        "geneSymbol": "GNAQ",
        "terms": [
            "GNAQ",
            "CMC1",
            "G-ALPHA-q",
            "GAQ",
            "SWS"
        ]
    },
    "variant": "Q209L",
    "createDate": "05/12/2014",
    "updateDate": "10/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 101965,
        "transcript": "NM_002072",
        "gDna": "chr9:g.77794572T>A",
        "cDna": "c.626A>T",
        "protein": "p.Q209L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16781,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest and apoptosis in a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 30567972).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 8196,
                "therapyName": "FR900359",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14908,
                    "pubMedId": 30567972,
                    "title": "Effects of Oncogenic G\u03b1q and G\u03b111 Inhibition by FR900359 in Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30567972"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10591,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 5564,
                "therapyName": "NAV-2729",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8662,
                    "pubMedId": 27265506,
                    "title": "ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27265506"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 2275,
                "therapyName": "AEB071 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 772,
                    "pubMedId": 24141786,
                    "title": "Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10583,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human uveal melanoma cell lines harboring GNAQ Q209L demonstrated sensitivity to Sotrastaurin (AEB071) in culture, and Sotrastaurin (AEB071) decreased tumor growth in uveal melanoma cell line xenograft models harboring GNAQ Q209L (PMID: 24141786).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 621,
                "therapyName": "AEB071",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 772,
                    "pubMedId": 24141786,
                    "title": "Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10642,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8697,
                    "pubMedId": 22733540,
                    "title": "Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22733540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8702,
                    "pubMedId": 19078957,
                    "title": "Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19078957"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8697,
                    "pubMedId": 22733540,
                    "title": "Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22733540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 1682,
                "therapyName": "Enzastaurin",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 982,
                    "pubMedId": 22253748,
                    "title": "The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22253748"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10632,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 3319,
                "therapyName": "Verteporfin",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8675,
                    "pubMedId": 27308390,
                    "title": "YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27308390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8672,
                    "pubMedId": 22515704,
                    "title": "Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22515704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165).",
            "molecularProfile": {
                "id": 561,
                "profileName": "GNAQ Q209L"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8677,
                    "pubMedId": 22550165,
                    "title": "Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22550165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10644,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",
            "molecularProfile": {
                "id": 27655,
                "profileName": "GNAQ Q209L PTEN R173S"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1752,
                "name": "ocular melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1066,
                    "pubMedId": 23434733,
                    "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 561,
            "profileName": "GNAQ Q209L",
            "profileTreatmentApproaches": [
                {
                    "id": 11239,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "GNAQ Q209L"
                },
                {
                    "id": 11236,
                    "name": "PKC Inhibitor (Pan)",
                    "profileName": "GNAQ Q209L"
                },
                {
                    "id": 11238,
                    "name": "Verteporfin",
                    "profileName": "GNAQ Q209L"
                },
                {
                    "id": 11237,
                    "name": "PKC beta Inhibitor",
                    "profileName": "GNAQ Q209L"
                }
            ]
        },
        {
            "id": 27655,
            "profileName": "GNAQ Q209L PTEN R173S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 101965,
            "transcript": "NM_002072",
            "gDna": "chr9:g.77794572T>A",
            "cDna": "c.626A>T",
            "protein": "p.Q209L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}